Pneumococcal Vaccine
8
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Trial of Simplified Pneumococcal Vaccination in Vietnam II
Pneumococcal Vaccination in Patients with Anti-TNF Alpha Therapy
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
Assessment of Knowledge on Pneumococcal Vaccination Among Diabetologists in India
Burden of Hospitalized Pneumonia in Korea COPD Population
Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea